Vera Therapeutics VERA 深 滬
已收盤 08-07 16:00:00 美东时间
32.89
+0.870
+2.72%
華盛通- 最 高33.0937
- 今 開32.81
- 成交量 151.52万股
- 最 低 32.085
- 昨 收 32.02
- 總市值 23.61亿
- 52周最高 56.05
- 市盈率 靜 --
- 換手率 2.11%
- 52周最低 21.15
- 委 比 47.37%
- 總股本 7178.29万
- 歷史最高 56.05
- 量 比 0.57
- 振 幅 3.15%
- 歷史最低 5.20
- 每 手 1
- 風險率 8.24%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics granted inducement awards, including stock options and RSUs, to its new Chief Regulatory Officer Nancy Bowman and two other employees under the 2024 Inducement Plan. The awards, valued at Vera's closing stock prices on August 3 and 4, 2026, will vest over four years. Vera Therapeutics is a biotech company focused on autoimmune diseases, with its flagship product TRUTAKNA™.
08-07 20:05
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics于2026年7月6日授予8名新员工总计32,100股非合格股票期权及16,050股限制性股票单位（RSU），依据其2024年激励计划。股票期权行权价为每股40.13美元，归属期为4年，其中25%在首年归属，剩余部分在36个月内按月归属。RSU同样归属4年，每年8月20日归属25%。Vera Therapeutics是一家专注于自身免疫疾病的生物技术公司，总部位于加利福尼亚州布里斯班。
07-10 20:05
Vera Therapeutics Announces New Chief Regulatory Officer
Vera Therapeutics ( ($VERA) ) has issued an announcement. On July 9, 2026, Vera...
07-09 20:30
美股大行评级 | 潜在涨幅215.37%！摩根士丹利上调TeraWulf(WULF)目标价至72美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持TeraWulf"超配"评级，目标价从66.5美元升至72美元；HC Wainwright & Co.：维持Vera Therapeutics"买入"评级，目标价从110美元升至125美元
07-09 12:35
美股大行评级 | 最高800美元！16家大行首予SpaceX"买入"或"超配"评级；奥本海上调康宁目标价从210美元升至230美元
今日重点评级关注：Canaccord Genuity：维持AtaiBeckley"买入"评级，目标价从15美元升至17美元；Truist Securities：维持NUVATION BIO"买入"评级，目标价从12美元升至13美元
07-08 15:31
B of A Securities Maintains Buy on Vera Therapeutics, Raises Price Target to $70
B of A Securities analyst Dina Ramadane maintains Vera Therapeutics (NASDAQ:VERA) with a Buy and raises the price target from $65 to $70.
07-08 02:54
Why Is Vera Therapeutics Stock Gaining Tuesday?
The U.S. Food and Drug Administration on Tuesday granted accelerated approval to Vera Therapeutics Inc.’s (NASDAQ:VERA) Trutakna (atacicept-vymj) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression. Following the announcement, the ...
07-08 02:15
Vera Therapeutics gains FDA nod for TRUTAKNA launch
An announcement from Vera Therapeutics ( ($VERA) ) is now available. On July 7,...
07-08 01:18
Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy
Vera Therapeutics announced FDA approval of TRUTAKNA (atacicept-vymj), the first and only therapy targeting both BAFF and APRIL, for reducing proteinuria in adults with primary IgA nephropathy (IgAN) at risk of progression. TRUTAKNA demonstrated a 46% reduction in proteinuria at 36 weeks in the ORIGIN 3 trial, with a 42% improvement over placebo (p<0.0001). The weekly 150 mg subcutaneous injection is self-administered at home. Common side effects...
07-07 16:37
